Translating Personalized Medicine Using New Genetic Technologies in Clinical Practice: the Ethical Issues

Overview

Journal Per Med

Specialties General Medicine
Genetics

Date 2014 Sep 16

PMID 25221608

Citations 16

Authors

Kelly E Ormond

Mildred K Cho

Affiliations

Soon will be listed here.

Abstract

The integration of new genetic technologies into clinical practice holds great promise for the personalization of medical care, particularly the use of large-scale DNA sequencing for genome-wide genetic testing. However, these technologies also yield unprecedented amounts of information whose clinical implications are not fully understood, and we are still developing technical standards for measuring sequence accuracy. These technical and clinical challenges raise ethical issues that are similar to but qualitatively different from those that we are accustomed to dealing with for traditional medical genetics. The sheer amount of information afforded by genome sequencing requires rethinking of how to implement core ethical principles including, but not limited to: informed consent, privacy and data ownership and sharing, technology regulation, issues of access, particularly as new technology is integrated into clinical practice, and issues of potential stigma and impact on perceptions of disability. In this article, we will review the issues of informed consent, privacy, data ownership and technology regulation as they relate to the emerging field of personalized medicine and genomics.

Citing Articles

The Use of Big Data in Personalized Healthcare to Reduce Inventory Waste and Optimize Patient Treatment.

Badr Y, Abdul Kader L, Shamayleh A J Pers Med. 2024; 14(4).

PMID: 38673011 PMC: 11051308. DOI: 10.3390/jpm14040383.

A Comprehensive Review of Genetic Variations in Collagen-Encoding Genes and Their Implications in Intervertebral Disc Degeneration.

Goel S, Deshpande S, Dhaniwala N, Singh R, Suneja A, Jadawala V Cureus. 2024; 16(1):e52708.

PMID: 38384607 PMC: 10880043. DOI: 10.7759/cureus.52708.

Healthcare practice strategies for integrating personalized medicine: Management of COVID-19.

Liu W, Chien C, Tung T World J Clin Cases. 2021; 9(29):8647-8657.

PMID: 34734043 PMC: 8546804. DOI: 10.12998/wjcc.v9.i29.8647.

Engaging pharmacogenomics in pain management and opioid selection.

Bright D, Petry N, Roath E, Gibb T Pharmacogenomics. 2021; 22(14):927-937.

PMID: 34521258 PMC: 8656342. DOI: 10.2217/pgs-2021-0044.

Practicality of 3D Printed Personalized Medicines in Therapeutics.

Amekyeh H, Tarlochan F, Billa N Front Pharmacol. 2021; 12:646836.

PMID: 33912058 PMC: 8072378. DOI: 10.3389/fphar.2021.646836.

References

Ormond K, Cirino A, Helenowski I, Chisholm R, Wolf W . Assessing the understanding of biobank participants. Am J Med Genet A. 2009; 149A(2):188-98. DOI: 10.1002/ajmg.a.32635. View

Michie S, Bobrow M, Marteau T . Predictive genetic testing in children and adults: a study of emotional impact. J Med Genet. 2001; 38(8):519-26. PMC: 1734924. DOI: 10.1136/jmg.38.8.519. View

Borry P, van Hellemondt R, Sprumont D, Jales C, Rial-Sebbag E, Spranger T . Legislation on direct-to-consumer genetic testing in seven European countries. Eur J Hum Genet. 2012; 20(7):715-21. PMC: 3376265. DOI: 10.1038/ejhg.2011.278. View

Kaye J . The regulation of direct-to-consumer genetic tests. Hum Mol Genet. 2008; 17(R2):R180-3. PMC: 2672785. DOI: 10.1093/hmg/ddn253. View

Green R, Berg J, Berry G, Biesecker L, Dimmock D, Evans J . Exploring concordance and discordance for return of incidental findings from clinical sequencing. Genet Med. 2012; 14(4):405-10. PMC: 3763716. DOI: 10.1038/gim.2012.21. View

Green R, Berg J, Grody W, Kalia S, Korf B, Martin C . ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013; 15(7):565-74. PMC: 3727274. DOI: 10.1038/gim.2013.73. View

Codori A, Zawacki K, Petersen G, Miglioretti D, Bacon J, Trimbath J . Genetic testing for hereditary colorectal cancer in children: long-term psychological effects. Am J Med Genet A. 2002; 116A(2):117-28. DOI: 10.1002/ajmg.a.10926. View

Hollegaard M, Grauholm J, Nielsen R, Grove J, Mandrup S, Hougaard D . Archived neonatal dried blood spot samples can be used for accurate whole genome and exome-targeted next-generation sequencing. Mol Genet Metab. 2013; 110(1-2):65-72. DOI: 10.1016/j.ymgme.2013.06.004. View

Lwoff L . Council of Europe adopts protocol on genetic testing for health purposes. Eur J Hum Genet. 2009; 17(11):1374-7. PMC: 2986683. DOI: 10.1038/ejhg.2009.84. View

10.

Ormond K, Wheeler M, Hudgins L, Klein T, Butte A, Altman R . Challenges in the clinical application of whole-genome sequencing. Lancet. 2010; 375(9727):1749-51. DOI: 10.1016/S0140-6736(10)60599-5. View

11.

Korf B, Rehm H . New approaches to molecular diagnosis. JAMA. 2013; 309(14):1511-21. DOI: 10.1001/jama.2013.3239. View

12.

Walsh T, Casadei S, Coats K, Swisher E, Stray S, Higgins J . Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006; 295(12):1379-88. DOI: 10.1001/jama.295.12.1379. View

13.

Malin B, Sweeney L . Re-identification of DNA through an automated linkage process. Proc AMIA Symp. 2002; :423-7. PMC: 2243547. View

14.

. Additional protocol to the convention on human rights and biomedicine, concerning genetic testing for health purposes. Rev Derecho Genoma Hum. 2008; (28):219-42. View

15.

McGuire A, Joffe S, Koenig B, Biesecker B, McCullough L, Blumenthal-Barby J . Point-counterpoint. Ethics and genomic incidental findings. Science. 2013; 340(6136):1047-8. PMC: 3772710. DOI: 10.1126/science.1240156. View

16.

Rienhoff Jr H, Yeo C, Morissette R, Khrebtukova I, Melnick J, Luo S . A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome. Am J Med Genet A. 2013; 161A(8):2040-6. PMC: 3885154. DOI: 10.1002/ajmg.a.36056. View

17.

Manning M, Hudgins L . Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. Genet Med. 2010; 12(11):742-5. PMC: 3111046. DOI: 10.1097/GIM.0b013e3181f8baad. View

18.

Annunziata C, Bates S . PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer. F1000 Biol Rep. 2010; 2. PMC: 2948351. DOI: 10.3410/B2-10. View

19.

Goldenberg A, Dodson D, Davis M, Tarini B . Parents' interest in whole-genome sequencing of newborns. Genet Med. 2013; 16(1):78-84. PMC: 4164384. DOI: 10.1038/gim.2013.76. View

20.

Hodgson J, Gaff C . Enhancing family communication about genetics: ethical and professional dilemmas. J Genet Couns. 2012; 22(1):16-21. DOI: 10.1007/s10897-012-9514-x. View